

LPL - PRODUCTION TEST COLLECTION CENTRE SECTOR - 18, BLOCK-E ROHINI DELHI 110085

Name DUMMY

Collected Received

Reported

: 4/6/2021 11:18:00AM : 4/6/2021 11:23:07AM

Lab No. : DUMMYZ005 Age: 25 Years Male Gender: Ref By: DR. DUMMY DUMMY A/c Status : P

: 5/6/2021 8:19:59PM

: Final **Report Status**

Test Name	Results	Units	Bio. Ref. Interval
LIVER PANEL 1; LFT,SERUM		~	
AST (SGOT) (IFCC without P5P)	<10	U/L	15.00 - 40.00
ALT (SGPT) (IFCC without P5P)	<10	U/L	10.00 - 49.00
AST:ALT Ratio (Calculated)	1.00	$\mathcal{Q}_{\mathcal{A}}$	<1.00
GGTP (IFCC)	<10	U/L	0 - 73
Alkaline Phosphatase (ALP) (IFCC-AMP)	<30	U/L	30.00 - 120.00
Bilirubin Total (DPD)	0.90	mg/dL	0.30 - 1.20
Bilirubin Direct (DPD)	0.20	mg/dL	<0.3
Bilirubin Indirect (Calculated)	0.70	mg/dL	<1.10
Total Protein (Biuret)	>12.00	g/dL	5.70 - 8.20
Albumin (BCG)	2.00	g/dL	3.20 - 4.80
A : G Ratio (Calculated)	0.10		0.90 - 2.00

Note

In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.



Page 1 of 2



LPL - PRODUCTION TEST COLLECTION CENTRE **SECTOR - 18, BLOCK-E ROHINI DELHI 110085**

Name DUMMY Collected

: 4/6/2021 11:18:00AM

Lab No.

: DUMMYZ005 Age: 25 Years Received Reported

: 4/6/2021 11:23:07AM : 5/6/2021 8:19:59PM

A/c Status P

Ref By: DR. DUMMY DUMMY

: Final **Report Status**

Test Name Results Units Bio. Ref. Interval

Male

2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of advanced liver fibrosis.

Gender:

- 3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.
- 4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can be used to assess risk for development of Hepatocellular Carcinoma.

Dr Himangshu Mazumdar MD, Biochemistry Senior Consultant - Clinical Chemistry & Biochemical Genetics NRL - Dr Lal PathLabs Ltd

Dr.Kamal Modi MD, Biochemistry

Consultant Biochemist NRL - Dr Lal PathLabs Ltd Dr Nimmi Kansal MD, Biochemistry

National Head - Clinical Chemistry &

Biochemical Genetics NRL - Dr Lal PathLabs Ltd

-End of report --

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted.*All test results are dependent on the quality of the sample received by the Laboratory *Laboratory investigations are only a <mark>tool</mark> to fa<mark>cilitat</mark>e in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample repeats are accepted on req<mark>uest of Ref</mark>erring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 7<mark>2 hours</mark> post reporti<mark>ng.*</mark>Test results may show interlaboratory variations.*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. *Contact customer care Tel No. +91-11-39885050 for all queries related to test results. (#) Sample drawn from outside source.

